{"id":"W4318904300","doi":"10.1200/jco.2023.41.4_suppl.394","title":"Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Cancer; Clinical endpoint; Adverse effect; Clinical trial; Oncology; Discontinuation; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001669054,0.001600375,0.001286641,0.0004818056,0.0004297886,0.0007609794,0.0007390526,0.001085544,0.005910814],"category_scores_gemma":[0.0007994831,0.0005876788,0.001097799,0.0002882798,0.0005634,0.0005845529,0.0004324379,0.002321636,0.00114834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001548515,"about_ca_system_score_gemma":0.001972592,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001702716,"about_ca_topic_score_gemma":0.004786278,"domain_scores_codex":[0.9995863,0.000214371,0.00001572773,0.00006519459,0.00003876461,0.00007966994],"domain_scores_gemma":[0.9995921,0.00005833082,0.00009344166,0.00002583768,0.00003035392,0.0001999107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8393139,0.03804531,0.005333614,0.001196264,0.001202839,0.0002575248,0.000216545,0.001837629,0.03368337,0.0002809402,0.008179303,0.07045276],"study_design_scores_gemma":[0.7403648,0.2454078,0.006597498,0.00004672139,0.0003358196,0.0002376299,0.00003724776,0.0007882316,0.002542102,0.0002203587,0.003403851,0.00001797145],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824334,0.003126157,0.0004872652,0.000851519,0.0001753297,0.006844304,0.002715258,0.0001455175,0.003221241],"genre_scores_gemma":[0.977749,0.001977184,0.002719693,0.0013116,0.0001733925,0.006165312,0.004662992,0.00004799162,0.005192753],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005910814,"threshold_uncertainty_score":0.01977366,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1358713147359017,"score_gpt":0.5253662221665132,"score_spread":0.3894949074306114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}